Xeris Biopharma: Q3 Earnings Reveals Strong Growth And Path To Breakeven

Nov. 12, 2022 12:15 AM ETXeris Biopharma Holdings, Inc. (XERS)16 Comments


  • Xeris Biopharma reported its Q3 earnings with a beat on EPS and revenue. Xeris reported strong growth with record net product revenue rising 17% from the previous quarter.
  • Xeris looks to be on track to hit its goal of cash flow breakeven by the end of 2023.
  • XERS is still trading around $1.50 per share and is down roughly 25% over the past twelve months. I believe XERS offers a great speculative opportunity at these prices.
  • I am making XERS a “Top Idea” in my Compounding Healthcare Marketplace Service.
  • I update my strategy to take advantage of these current prices.
  • Looking for a portfolio of ideas like this one? Members of Compounding Healthcare get exclusive access to our subscriber-only portfolios. Learn More »

glowing graph 2

Jonathan Kitchen

Xeris Biopharma (NASDAQ:XERS) recently reported their Q3 earnings with a beat on EPS and revenue. The earnings revealed strong growth with record net product revenue rising 17% from the previous quarter and 31% over Q3 of 2021. Xeris appears

Xeris Biopharma Products and Markets

Xeris Biopharma Products and Markets (Xeris Biopharma)

Xeris Biopharma Pipeline

Xeris Biopharma Pipeline (Xeris Biopharma)

Xeris Annual Revenue Estimates

Xeris Annual Revenue Estimates (Seeking Alpha)

XERS Daily Chart

XERS Daily Chart (Trendspider)

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare, and sign up for a free trial.

This article was written by

Biologics profile picture
Diagnosing the market to compound capital in the healthcare sector.

After years of working in the medical field, I have developed a passion for biotech and lifesaving therapies. Now, I am a full-time healthcare investor who is in search of the next breakthrough therapy, device, or pharmaceutical. My trade focus is around catalysts and potential acquisitions. In addition, I provide a marketplace service, Compounding Healthcare through Seeking Alpha.

Disclosure: I/we have a beneficial long position in the shares of XERS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (16)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.